Doctors at the West Siberian Medical Center, part of the Russian Federal Agency for Medicine and Biology, completed a complex operation to remove large ovarian metastases from a patient. The procedure lasted about two hours, and the medical team reported the successful outcome through the center’s press service.
The operation involved the removal of a substantial ovarian metastasis from a 59-year-old woman from Omsk. The patient had been battling cancer for two decades and remained under oncologist supervision throughout that time. She underwent several rounds of chemotherapy, and in 2017 the tumor began to grow more rapidly, signaling a progression that required careful surgical assessment and intervention.
According to the center, the case presented multiple challenges. The tumor was recurrent, with several metastatic sites. The team identified three metastatic tumors: two small foci within the pelvic region and a large, visually prominent localization measuring approximately 15 centimeters in length and 20 centimeters in height. Such a presentation is considered rare and demanding, underscoring the complexity of treating advanced metastatic disease in the ovarian region.
The surgical team successfully removed metastases weighing about two kilograms. After the operation, the patient was placed under ongoing medical supervision and scheduled for follow-up evaluations with oncologists to monitor recovery and assess the need for additional treatment options.
Reports from the medical center emphasize the importance of multidisciplinary care in managing advanced ovarian cancer with metastases. The team coordinated surgical techniques with systemic therapies and imaging studies to guide the procedure and ensure optimal outcomes for the patient. Ongoing follow-up is essential to track response to treatment, manage potential complications, and maintain the patient’s quality of life throughout the recovery process.
In related news, medical centers across the region continue to advance strategies for handling large ovarian tumors and metastatic disease. These efforts reflect a broader commitment to improving survival and functional outcomes for patients facing complex oncologic challenges.